[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 68 of about 68
1. Brody JR, Witkiewicz A, Williams TK, Kadkol SS, Cozzitorto J, Durkan B, Pasternack GR, Yeo CJ: Reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia. Mod Pathol; 2007 Dec;20(12):1238-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia.
  • Nuclear phosphoprotein 32 (pp32) inhibits K-ras induced transformation in experimental models. pp32 mRNA expression correlates with differentiation status in breast and prostate cancers.
  • In this study, we evaluated pp32 protein expression in relation to the differentiation status of pancreatic ductal adenocarcinomas and precursor lesions of the pancreatic cancers. pp32 expression showed strong nuclear staining in normal pancreatic acini and ducts.
  • The intensity of this staining was maintained in pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasms with mild dysplasia, well-differentiated adenocarcinomas, and in a subset of moderately differentiated adenocarcinomas. pp32 staining was absent or reduced in poorly differentiated tumors and in intraductal papillary mucinous neoplasms with moderate dysplasia.
  • We validated pp32 expression by a second technique, immunoblot analysis of lysates from resected pancreatic ductal adenocarcinomas and pancreatic cancer cell lines.
  • On the basis of this study and previous functional work that shows pp32 can inhibit K-ras transformation, we propose that reduction in pp32 expression levels may be a critical event in the progression of pancreatic tumorigenesis in an aggressive subset of pancreatic ductal adenocarcinomas.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / pathology. Nuclear Proteins / biosynthesis. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Biomarkers, Tumor / analysis. Gene Expression. Humans. Immunoblotting. Immunohistochemistry. Phosphoproteins / biosynthesis. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17906614.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Phosphoproteins
  •  go-up   go-down


2. Ko ES, Cho N, Cha JH, Park JS, Kim SM, Moon WK: Sonographically-guided 14-gauge core needle biopsy for papillary lesions of the breast. Korean J Radiol; 2007 May-Jun;8(3):206-11
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonographically-guided 14-gauge core needle biopsy for papillary lesions of the breast.
  • OBJECTIVE: We wanted to assess the need for surgical excising papillary lesions of the breast that were diagnosed upon sonographically guided 14-gauge core needle biopsy.
  • MATERIALS AND METHODS: Sixty-nine women (age range: 25-74 years, mean age: 51.7 years) with 69 papillary lesions (4.9%) were diagnosed and followed after performing sonographically guided 14-gauge core needle biopsies.
  • Surgical excision was performed for 44 (64%) of 69 papillary lesions, and 25 lesions were followed with imaging studies (range: 6-46 months, mean: 17.9 months).
  • Of the 43 lesions that yielded benign papilloma upon core needle biopsy, one had intraductal papillary carcinoma found upon surgery.
  • No additional carcinoma was found during the imaging follow-up.
  • Surgical excision was performed for 17 atypical papillary lesions, and this revealed intraductal (n = 6) or invasive (n = 2) papillary carcinoma in 8 (47%) lesions.
  • Of the seven intraductal papillary carcinomas, surgery revealed invasive papillary carcinoma in one (14%).
  • CONCLUSION: Our results suggest that papillary lesions of the breast that are diagnosed as benign upon sonographically guided 14-gauge core needle biopsy can be followed when the results are concordant with the imaging findings.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Papilloma, Intraductal / pathology. Ultrasonography, Interventional
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Carcinoma / pathology. Carcinoma / surgery. Female. Humans. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2001 Dec;221(3):650-5 [11719659.001]
  • [Cites] AJR Am J Roentgenol. 2002 Nov;179(5):1185-92 [12388496.001]
  • [Cites] Radiology. 1993 May;187(2):507-11 [8475299.001]
  • [Cites] AJR Am J Roentgenol. 1994 Apr;162(4):815-20 [8140997.001]
  • [Cites] Radiology. 1994 Nov;193(2):359-64 [7972743.001]
  • [Cites] Radiology. 1997 Mar;202(3):843-7 [9051043.001]
  • [Cites] Radiology. 1998 Apr;207(1):191-9 [9530316.001]
  • [Cites] Radiology. 1998 Sep;208(3):717-23 [9722851.001]
  • [Cites] AJR Am J Roentgenol. 1999 Feb;172(2):331-7 [9930777.001]
  • [Cites] Radiology. 1999 Mar;210(3):799-805 [10207484.001]
  • [Cites] AJR Am J Roentgenol. 1999 Oct;173(4):921-7 [10511149.001]
  • [Cites] Korean J Radiol. 2005 Apr-Jun;6(2):102-9 [15968149.001]
  • [Cites] Radiology. 2006 Mar;238(3):801-8 [16424237.001]
  • [Cites] AJR Am J Roentgenol. 2006 May;186(5):1328-34 [16632727.001]
  • [Cites] Radiology. 2002 Aug;224(2):569-76 [12147858.001]
  • (PMID = 17554187.001).
  • [ISSN] 1229-6929
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2627411
  •  go-up   go-down


3. Goh PG, Moon HS, Sung JK, Jeong HY, Song KS: [A case of Peutz-Jeghers syndrome with intraductal papillary mucinous carcinoma of pancreas]. Korean J Gastroenterol; 2010 Jan;55(1):73-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of Peutz-Jeghers syndrome with intraductal papillary mucinous carcinoma of pancreas].
  • In particular, many studies have reported that patients with this syndrome have a high risk of gastrointestinal or extragastrointestinal malignancy including gastric, duodenal, jejunal, ileal, and colonic carcinoma as well as malignancies involving other organs such as the gallbladder, biliary tract, pancreas, tonsils, breast, and reproductive system.
  • In addition to that, there is no reported case of this syndrome with malignant tumor or intraductal papillary mucinous tumor of pancreas in Korea.
  • We experienced a case of PJS accompanying intraductal papillary mucinous carcinoma of the pancreas, therefore we report this case with literatures reviewed.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Papillary / diagnosis. Pancreatic Neoplasms / diagnosis. Peutz-Jeghers Syndrome / diagnosis

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098071.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


Advertisement
4. Yokomuro S, Arima Y, Mizuguchi Y, Shimizu T, Kawahigashi Y, Kannda T, Arai M, Uchida E, Akimaru K, Tajiri T: Mucin-producing bile duct carcinoma arising from primary sclerosing cholangitis: a case report. J Nippon Med Sch; 2007 Feb;74(1):61-4
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin-producing bile duct carcinoma arising from primary sclerosing cholangitis: a case report.
  • The patient did not have ulcerative colitis or pancreatic intraductal papillary mucinous neoplasm.
  • Repeated cytologic examinations of the bile showed atypical cells consistent with adenocarcinoma.
  • The patient underwent extended resection of the left lobe of the liver and was found to have intraductal papillary carcinoma with associated mucin-producing bile duct carcinoma.
  • This carcinoma fills dilated bile duct lumens with mucin.
  • Just one case of mucin-producing bile duct carcinoma arising from PSC has been reported worldwide.
  • Patients with mucin-producing bile duct carcinoma, as in the case of its pancreatic counterpart, may have a better prognosis and a higher survival rate than patients with typical cholangiocarcinomas.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Bile Duct Neoplasms / surgery. Cholangitis, Sclerosing / complications

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17384480.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Okada K, Suzuki Y, Saito Y, Umemura S, Tokuda Y: Two cases of ductal adenoma of the breast. Breast Cancer; 2006;13(4):354-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of ductal adenoma of the breast.
  • We encountered two cases of ductal adenoma of the breast.
  • In the first case, a 32-year-old woman presented with a two-year history of a left breast lump.
  • On excisional biopsy of the largest , intraoperative pathological examination of frozen sections was suspicious for ductal carcinoma with a differential diagnosis of intraductal papilloma or intraductal papillary carcinoma.
  • Ductal adenoma was diagnosed after pathological examination of the permanent sections.
  • The second case was a 64-year-old woman who presented with a hard lump in her left breast.
  • Mammography and ultrasonography demonstrated images typical of carcinoma.
  • Ductal adenoma (sclerosing papilloma) with hemorrhagic infarction was diagnosed.
  • It is noteworthy that ductal adenoma have clinical and histopathological features that should be differentiated from carcinoma, especially when the tumor is accompanied by secondary changes such as hemorrhage or infarction.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Breast / blood supply. Breast / pathology. Diagnosis, Differential. Female. Hemorrhage / etiology. Humans. Infarction / etiology. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17146162.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Pant I, Joshi SC: Invasive papillary carcinoma of the male breast: report of a rare case and review of the literature. J Cancer Res Ther; 2009 Jul-Sep;5(3):216-8
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive papillary carcinoma of the male breast: report of a rare case and review of the literature.
  • Breast masses occur in men far less commonly than women.
  • Papillary lesions of the male breast are rare and comprise a spectrum of lesions ranging from benign intraductal papilloma to intraductal papillary carcinoma and invasive papillary carcinoma.
  • A diagnosis of papillary lesion favoring papillary carcinoma was rendered.
  • The patient underwent modified radical mastectomy, which showed invasive papillary carcinoma.
  • As far as we know, only a few cases of invasive papillary carcinoma of the male breast have been published in the literature.
  • To the best of our knowledge, this is the first case report of invasive papillary carcinoma of male breast in Malaysia.
  • In this purview, we discuss papillary carcinoma of male breast with review of the relevant literature.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Carcinoma, Papillary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19841568.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 10
  •  go-up   go-down


7. Sparr JA, Bandipalliam P, Redston MS, Syngal S: Intraductal papillary mucinous neoplasm of the pancreas with loss of mismatch repair in a patient with Lynch syndrome. Am J Surg Pathol; 2009 Feb;33(2):309-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm of the pancreas with loss of mismatch repair in a patient with Lynch syndrome.
  • Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a precancerous lesion with a well-described progression to carcinoma.
  • The patient's adenocarcinoma of the colon and IPMN of the pancreas showed identical immunohistochemical staining profiles with loss of expression of MSH2 and MSH6 proteins and high levels of microsatellite instability.
  • The immunohistochemical staining and microsatellite instability patterns of the adenocarcinoma of the colon and IPMN gives strong evidence to support the consideration of IPMN as part of the spectrum of lesions found in Lynch syndrome.

  • Genetic Alliance. consumer health - Lynch syndrome.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Genet. 1999 Nov;36(11):801-18 [10544223.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):444-9 [18398828.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3139-44 [11306499.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):942-8 [11420467.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2017-22 [11733352.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):537-42 [12808058.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):235-8 [14760534.001]
  • [Cites] Br J Cancer. 1985 Aug;52(2):271-3 [4027169.001]
  • [Cites] Cancer. 1991 Sep 1;68(5):1109-12 [1913482.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):677-85 [8431847.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1020-7 [8612988.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1501-7 [9626054.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):470-3 [10022648.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):214-8 [10188721.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] J Clin Pathol. 2005 Jan;58(1):97-101 [15623495.001]
  • [Cites] Arch Surg. 2006 Jan;141(1):51-6; discussion 56 [16415411.001]
  • [Cites] Hum Pathol. 2006 Nov;37(11):1498-502 [16996571.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):803-13; discussion 813-4 [17481488.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):831-49, vi [17996793.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1641-51 [10793075.001]
  • (PMID = 18987546.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K24 CA113433; United States / NCI NIH HHS / CA / K24 CA113433-04; United States / PHS HHS / / K24-113433
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  • [Other-IDs] NLM/ NIHMS77744; NLM/ PMC2631097
  •  go-up   go-down


8. Adachi T, Tajima Y, Kuroki T, Mishima T, Kitasato A, Fukuda K, Tsutsumi R, Kanematsu T: Bile-reflux into the pancreatic ducts is associated with the development of intraductal papillary carcinoma in hamsters. J Surg Res; 2006 Nov;136(1):106-11
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bile-reflux into the pancreatic ducts is associated with the development of intraductal papillary carcinoma in hamsters.
  • BACKGROUND: Reflux of pancreatic juice into the biliary tract is a well-known risk factor for the development of biliary carcinoma.
  • In this study, we investigated the significance of bile-reflux into the pancreatic ducts in pancreatic carcinogenesis, especially in the development of carcinoma in the main pancreatic duct in hamsters.
  • RESULTS: Pancreas carcinomas developed in 95, 88, and 90% of the Model A hamsters (n = 22), B (n = 24), and C (n = 21), respectively.
  • The induced pancreatic tumors were histologically classified into four types: papillary; tubular; cystic adenocarcinoma; or intraductal carcinoma of the main pancreatic duct consisting of intraductal papillary carcinoma (IPC) and intraductal tubular carcinoma (ITC).
  • [MeSH-major] Adenocarcinoma / etiology. Bile Reflux / complications. Carcinoma, Pancreatic Ductal / etiology. Carcinoma, Papillary / etiology. Pancreatic Neoplasms / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16863651.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / Carcinogens; 0 / Nitrosamines; 0 / Proliferating Cell Nuclear Antigen; 60599-38-4 / nitrosobis(2-oxopropyl)amine
  •  go-up   go-down


9. Moritani S, Ichihara S, Kushima R, Okabe H, Bamba M, Kobayashi TK, Hattori T: Myoepithelial cells in solid variant of intraductal papillary carcinoma of the breast: a potential diagnostic pitfall and a proposal of an immunohistochemical panel in the differential diagnosis with intraductal papilloma with usual ductal hyperplasia. Virchows Arch; 2007 May;450(5):539-47
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myoepithelial cells in solid variant of intraductal papillary carcinoma of the breast: a potential diagnostic pitfall and a proposal of an immunohistochemical panel in the differential diagnosis with intraductal papilloma with usual ductal hyperplasia.
  • We examined myoepithelial status in intraductal papillary carcinoma (IPC) along with the expression of high-molecular weight cytokeratin (HMWK) and neuroendocrine markers, with special reference to the differential diagnosis of solid intraductal papillary carcinoma(SIPC) and intraductal papilloma with usual ductal hyperplasia (IP-UDH).
  • Twenty-six (93%) of the twenty-eight intraductal papillomas (IP) had myoepithelial cells in >70% of the epithelial-stromal interface of the intraluminal proliferating component.
  • However, by using a combination of myoepithelial markers, HMWK, and neuroendocrine markers, all of the 36 solid intraductal papillary lesions were properly classified as benign and malignant.
  • Solid intraductal papillary lesions meeting at least two of the following criteria are highly likely to be malignant:.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Papillary / pathology. Mammary Glands, Human / pathology. Papilloma, Intraductal / pathology

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17377808.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nerve Tissue Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


10. Collins LC, Schnitt SJ: Papillary lesions of the breast: selected diagnostic and management issues. Histopathology; 2008 Jan;52(1):20-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary lesions of the breast: selected diagnostic and management issues.
  • The assessment and categorization of papillary lesions remains one of the most challenging areas in breast pathology.
  • In this review, we will focus on several diagnostic and management issues related to papillary breast lesions that are frequently encountered in daily practice.
  • These include: (i) the distinctions among papillomas with atypia (atypical papillomas), papillomas with ductal carcinoma in situ, and papillary ductal carcinoma in situ;.
  • (ii) recent developments in our understanding of encapsulated ('intracystic') papillary carcinomas and solid papillary carcinomas; and (iii) the impact of core needle biopsy on management decisions and specimen evaluation.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology
  • [MeSH-minor] Biopsy, Needle. Carcinoma in Situ / diagnosis. Carcinoma in Situ / pathology. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Intraductal, Noninfiltrating / pathology. Diagnosis, Differential. Female. Humans. Papilloma / diagnosis. Papilloma / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18171414.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 30
  •  go-up   go-down


11. Tan PH, Aw MY, Yip G, Bay BH, Sii LH, Murugaya S, Tse GM: Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ? Am J Surg Pathol; 2005 May;29(5):625-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ?
  • We studied 50 papillary lesions (25 papillomas and 25 papillary ductal carcinomas in situ, DCIS) diagnosed at Singapore General Hospital, for immunohistochemical expression of cytokeratin (CK) 5/6, CK14, and 34betaE12.
  • Results were applied to a separate series of 43 papillary tumors from Hong Kong (HK).
  • CK5/CK6, CK14, and 34betaE12 showed higher immunoscores in papillomas (mean values, 107.6, 186.6, and 113.1, respectively) than papillary DCIS (mean values, 12, 29.6, and 34.5, respectively; P<0.0001, P<0.001, and P<0.02, respectively).
  • A cutoff immunoscore threshold of 50 appeared discriminatory between papilloma and papillary DCIS, and this value was applied to the HK cases, with CK5/CK6, CK14, and 34betaE12 correctly predicting 25 (89.3%), 26 (92.9%), and 27 (96.4%), respectively, of 28 HK lesions labeled as papillomas; while they corroborated 13 (86.7%), 13 (86.7%), and 5 (33.3%), respectively, of 15 HK cases diagnosed as papillary DCIS.
  • Review of discordant cases showed that lesions were small, derived from core biopsies, or disclosed accompanying invasive carcinoma.
  • When both SGH and HK cases were combined as a group, the sensitivity of an immunoscore of 50 or less in the diagnosis of papillary DCIS was 95%, 85%, and 62.5% for CK5/CK6, CK14, and 34betaE12, respectively, while the specificity was 86.8%, 94.3%, and 86.8%, respectively.
  • CK immunohistochemistry can aid in evaluating papillary breast lesions.
  • 34betaE12 does not appear as useful in identifying papillary DCIS.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Papillary / pathology. Keratins / metabolism. Papilloma, Intraductal / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832086.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


12. Adachi T, Tajima Y, Kuroki T, Mishima T, Kitasato A, Tsuneoka N, Kanematsu T: Chemopreventive effects of a selective cyclooxygenase-2 inhibitor (etodolac) on chemically induced intraductal papillary carcinoma of the pancreas in hamsters. Carcinogenesis; 2008 Apr;29(4):830-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemopreventive effects of a selective cyclooxygenase-2 inhibitor (etodolac) on chemically induced intraductal papillary carcinoma of the pancreas in hamsters.
  • The present study was designed to determine whether etodolac, a selective cyclooxygenase-2 inhibitor, prevents chemically induced intraductal papillary carcinoma (IPC) in the main pancreatic duct of hamsters.
  • The incidence of induced pancreatic carcinoma was 93, 81 and 72% in groups CE, ET and ET4, respectively.
  • The pancreatic carcinomas were histologically classified into four types, i.e. tubular, papillary, cyst adenocarcinoma and IPC.
  • The proliferating cell nuclear antigen labeling indices in the non-cancerous epithelial cells of the main pancreatic duct were 2.8 and 6.8% in groups ET4 and ET, respectively, and were significantly lower than that in group CE (10.8%).
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Anticarcinogenic Agents / therapeutic use. Carcinoma, Pancreatic Ductal / drug therapy. Cyclooxygenase 2 / metabolism. Cyclooxygenase 2 Inhibitors / therapeutic use. Etodolac / therapeutic use
  • [MeSH-minor] Animals. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Cricetinae. Disease Models, Animal. Female. Kinetics. Mesocricetus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18296437.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Anticarcinogenic Agents; 0 / Cyclooxygenase 2 Inhibitors; 2M36281008 / Etodolac; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


13. Miyagawa M, Kanemasa H, Nitan T, Matsumoto M, Tokita K, Kajita Y, Yanagisawa A, Nakamura Y, Sonoyama T, Yamagishi H, Mitsufuji S, Okanoue T: [A case of minimal invasive carcinoma from intraductal papillary mucinous neoplasm with invasive ductal carcinoma of the pancreas]. Nihon Shokakibyo Gakkai Zasshi; 2006 Dec;103(12):1384-90
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of minimal invasive carcinoma from intraductal papillary mucinous neoplasm with invasive ductal carcinoma of the pancreas].
  • Intraductal papillary mucinous neoplasm (IPMN) of the branch pancreatic duct was diagnosed, and there was a likelihood of ductal carcinoma of the pancreas.
  • Pathological finding showed invasive carcinoma from an intraductal papillary mucinous neoplasm with invasive ductal carcinoma of the pancreas.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Cystadenocarcinoma, Mucinous / diagnosis. Neoplasms, Multiple Primary. Pancreatic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17148928.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Rabban JT, Koerner FC, Lerwill MF: Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6. Hum Pathol; 2006 Jul;37(7):787-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.
  • The solid papillary variant of ductal carcinoma in situ is an uncommon entity, which usually presents in the seventh or eighth decade and may be associated with invasive mucinous carcinoma.
  • Solid papillary ductal carcinoma in situ (SP-DCIS) shares many morphological features with usual ductal hyperplasia (UDH) involving a papilloma: papillary architecture, solid growth, cellular streaming, and low-grade nuclear features.
  • Recent studies have demonstrated that immunohistochemical staining for cytokeratin 5/6 can distinguish UDH from conventional forms of ductal carcinoma in situ.
  • Most of the epithelial cells of UDH express cytokeratin 5/6, but the tumor cells of ductal carcinoma in situ do not.
  • We tested the hypothesis that the results of staining for cytokeratin 5/6 can distinguish UDH from the solid papillary variant of ductal carcinoma in situ.
  • Immunohistochemical staining of 14 cases of SP-DCIS and 9 cases of UDH (4 involving papillomas) was performed using cytokeratin 5/6 antibody clone D5/16 B4.
  • None of the SP-DCIS tumor cells stained for cytokeratin 5/6; however, many cases did show staining of occasional entrapped, benign epithelial, and myoepithelial cells.
  • We conclude that the absence of strong cytokeratin 5/6 expression by SP-DCIS distinguishes it from its morphological mimic, UDH.
  • Pathologists must guard against misinterpreting SP-DCIS as UDH in those cases in which the carcinoma cells engulf cytokeratin 5/6-expressing residual, native epithelial cells.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Papillary / diagnosis. Keratins / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784976.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


15. Linda A, Zuiani C, Girometti R, Londero V, Machin P, Brondani G, Bazzocchi M: Unusual malignant tumors of the breast: MRI features and pathologic correlation. Eur J Radiol; 2010 Aug;75(2):178-84
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual malignant tumors of the breast: MRI features and pathologic correlation.
  • Unusual malignant breast tumors are well-differentiated subtypes of invasive ductal carcinoma, including mucinous, tubular, medullary and papillary carcinomas, and account for about 10% of malignant breast tumors.
  • They are increasingly being encountered during magnetic resonance imaging (MRI) examinations of the breast.
  • Therefore, breast radiologists should be aware of their appearance on MRI.
  • This review provides an overview of MRI characteristics of a range of unusual tumors (mucinous carcinoma, medullary carcinoma, tubular carcinoma, intraductal papillary carcinoma, intracystic papillary carcinoma and invasive papillary carcinoma), highlighting specific clues for diagnosis and correlating MRI and pathologic features.
  • Many unusual breast tumors exhibit MRI features similar to those of benign or low suspicious lesions (oval shape, well-defined margins, high signal intensity on T2-weighted images, continuous increase kinetics, i.e. type I dynamic curve), leading to a possible misdiagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast / pathology. Breast Neoplasms / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / pathology. Female. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19446418.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  •  go-up   go-down


16. Troxell ML, Masek M, Sibley RK: Immunohistochemical staining of papillary breast lesions. Appl Immunohistochem Mol Morphol; 2007 Jun;15(2):145-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining of papillary breast lesions.
  • The separation of ductal papilloma from intraductal papillary carcinoma of the breast on hematoxylin and eosin stained sections often presents diagnostic difficulty.
  • In this study, the staining characteristics of a panel of myoepithelial markers (calponin, p63, P-cadherin), were compared with SMA, and the epithelial expression of CD44s was assessed in 99 papillary lesions.
  • SMA, calponin, and p63 demonstrated myoepithelial cells in 61%, 63%, and 65% of papillary lesions, respectively.
  • However, p63 stained the epithelial component in one papillary carcinoma, a basal layer of cells in 1 biphasic invasive carcinoma, and the cytoplasm in 1 case.
  • The epithelial expression of CD44s and did not distinguish papillomas from papillary carcinomas.
  • Thus, P-cadherin and CD44s are not useful in the characterization of papillary lesions.
  • Given increased specificity as compared with SMA, the combination of p63 and calponin is recommended for analysis of breast papillary lesions.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525625.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD44; 0 / CKAP4 protein, human; 0 / Cadherins; 0 / Calcium-Binding Proteins; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / calponin
  •  go-up   go-down


17. Ingkakul T, Sadakari Y, Ienaga J, Satoh N, Takahata S, Tanaka M: Predictors of the presence of concomitant invasive ductal carcinoma in intraductal papillary mucinous neoplasm of the pancreas. Ann Surg; 2010 Jan;251(1):70-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of the presence of concomitant invasive ductal carcinoma in intraductal papillary mucinous neoplasm of the pancreas.
  • OBJECTIVE: Invasive ductal carcinoma (DC) of the pancreas arising as an independent lesion in association with intraductal papillary mucinous neoplasm (IPMN) has occasionally been reported.
  • Multivariate analysis revealed 2 significant predictive factors for the presence of DC in IPMN, including worsening diabetes mellitus (P < 0.001) and an abnormal serum CA 19-9 level (P = 0.024).
  • CONCLUSION: In view of the high prevalence of DC careful inspection of the entire pancreatic gland is necessary for early detection of DC in patients with branch duct IPMNs, especially when worsening diabetes mellitus and an abnormal serum CA 19-9 level are manifested.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009749.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Watanabe H, Okada G, Ohtsubo K, Yamaguchi Y, Mouri H, Motoo Y, Wakabayashi T, Sawabu N: Expression of mesothelin mRNA in pure pancreatic juice from patients with pancreatic carcinoma, intraductal papillary mucinous neoplasm of the pancreas, and chronic pancreatitis. Pancreas; 2005 May;30(4):349-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of mesothelin mRNA in pure pancreatic juice from patients with pancreatic carcinoma, intraductal papillary mucinous neoplasm of the pancreas, and chronic pancreatitis.
  • OBJECTIVES: In the gene expression analysis of pancreatic carcinoma (PCa) using serial analysis of gene expression (SAGE) according to Ryu et al, the tag for the mesothelin mRNA transcript was present in 7 of 8 SAGE libraries derived from PCa but not in the 2 SAGE libraries derived from normal pancreatic duct epithelial cells.
  • Mesothelin mRNA expression was confirmed with in situ hybridization in all 4 resected primary PCa tumors and with RT-PCR in 18 of 20 PCa cell lines, whereas mesothelin protein expression was confirmed with immunohistochemistry in all 60 resected primary PCa tissues by Argani et al.
  • We evaluated mesothelin mRNA expression in pure pancreatic juice (PPJ) obtained from patients with PCa, chronic pancreatitis (CP), and intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Papillary / diagnosis. Membrane Glycoproteins / genetics. Pancreatic Neoplasms / diagnosis. Pancreatitis, Chronic / diagnosis

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841046.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / RNA, Messenger; 0 / mesothelin
  •  go-up   go-down


19. Lam WW, Tang AP, Tse G, Chu WC: Radiology-Pathology conference: papillary carcinoma of the breast. Clin Imaging; 2005 Nov-Dec;29(6):396-400
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiology-Pathology conference: papillary carcinoma of the breast.
  • Papillary carcinoma of the breast is a rare breast carcinoma.
  • It can be classified into invasive and noninvasive types.
  • It can also be classified into intracystic and intraductal papillary carcinoma.
  • Pitfalls are found to be associated with fine needle aspiration and core biopsy in the evaluation of papillary lesions.
  • It is therefore important for radiologists to diagnose papillary carcinoma for proper management of the patients.
  • [MeSH-major] Breast Neoplasms / radiography. Breast Neoplasms / ultrasonography. Carcinoma, Papillary / radiography. Carcinoma, Papillary / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16274892.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


20. Kimura W: Pancreatic lithiasis and intraductal papillary-mucinous neoplasm with special reference to the pathogenesis of lithiasis. J Hepatobiliary Pancreat Sci; 2010 Nov;17(6):776-81
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic lithiasis and intraductal papillary-mucinous neoplasm with special reference to the pathogenesis of lithiasis.
  • Mucin production in epithelia in intraductal papillary-mucinous neoplasm (IPMN) may not be strongly associated with the pathogenesis of pancreatic lithiasis.
  • An increase in intraductal pressure of the pancreatic duct may be somewhat related to the mechanism of stone formation.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Lithiasis / diagnosis. Pancreas. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Mucinous. Cholangiopancreatography, Endoscopic Retrograde. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Pancreatitis, Chronic / diagnosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19779665.001).
  • [ISSN] 1868-6982
  • [Journal-full-title] Journal of hepato-biliary-pancreatic sciences
  • [ISO-abbreviation] J Hepatobiliary Pancreat Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  •  go-up   go-down


21. Riall TS, Stager VM, Nealon WH, Townsend CM Jr, Kuo YF, Goodwin JS, Freeman JL: Incidence of additional primary cancers in patients with invasive intraductal papillary mucinous neoplasms and sporadic pancreatic adenocarcinomas. J Am Coll Surg; 2007 May;204(5):803-13; discussion 813-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of additional primary cancers in patients with invasive intraductal papillary mucinous neoplasms and sporadic pancreatic adenocarcinomas.
  • BACKGROUND: Recent small studies have reported an incidence of 23% to 39% for additional primary cancers in patients with intraductal papillary mucinous neoplasms (IPMN) of the pancreas.
  • We determined the incidence of additional primary cancers that developed either before or after the diagnosis of invasive IPMN and compared it to the incidence of additional primary cancers in patients with sporadic pancreatic adenocarcinoma.
  • Ninety-five percent of cancers were sporadic and 5.0% were invasive IPMNs.
  • Ten point three percent had one or more extra-pancreatic primary cancers in addition to their pancreatic primary (10.3% in patients with sporadic adenocarcinoma and 10.1% in patients with invasive IPMNs, p = NS).
  • The most common sites of additional primary cancers were colorectal (20.1%), breast (19.9%), prostate (16.6%), urinary system (11.1%), and lung (9.8%).
  • CONCLUSIONS: Our population-based analysis shows that the incidence of additional primary malignancies in patients with invasive IPMNs is 10%.
  • Although not as high as previously reported in smaller studies, the incidence is significant and comparable to the incidence seen in patients with adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Pancreatic Ductal / epidemiology. Carcinoma, Papillary / epidemiology. Neoplasms, Multiple Primary / epidemiology. Pancreatic Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17481488.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Takasu N, Kimura W, Moriya T, Hirai I, Takeshita A, Kamio Y, Nomura T: Intraductal papillary-mucinous neoplasms of the gastric and intestinal types may have less malignant potential than the pancreatobiliary type. Pancreas; 2010 Jul;39(5):604-10
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary-mucinous neoplasms of the gastric and intestinal types may have less malignant potential than the pancreatobiliary type.
  • OBJECTIVES: Intraductal papillary-mucinous neoplasms (IPMNs) of the pancreas are classified into 4 types--gastric, intestinal, pancreatobiliary, and oncocytic--on the basis of their morphology and immunohistochemistry.
  • The intestinal and pancreatobiliary types had almost the same frequencies of carcinoma, but the intestinal type tended to have a lower frequency of invasive carcinoma than the pancreatobiliary type.
  • Patients with invasive carcinomas derived from intestinal-type IPMNs tended to have a better prognosis than those whose invasive carcinomas were derived from the pancreatobiliary type.
  • CONCLUSIONS: Intraductal papillary-mucinous neoplasm of the gastric and intestinal types may have less malignant potential than that of the pancreatobiliary type.
  • Invasive carcinomas derived from intestinal-type IPMNs may be less invasive and slower growing than those derived from the pancreatobiliary type.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Bile Duct Neoplasms / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Intestinal Neoplasms / pathology. Pancreatic Neoplasms / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20124938.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Ikeda M, Ryu M, Yamazaki K, Tsuchiya M, Kaneko H, Miyairi M: Long-term follow-up of a pouching operation after pancreaticoduodenectomy using a double-jejunal pouch. Hepatogastroenterology; 2007 Dec;54(80):2398-400
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 63-year old male was referred with intraductal papillary adenocarcinoma of the pancreas.
  • A modification of the Imanaga reconstructive method using a double-jejunal pouch was performed for the pancreatic carcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18265674.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


24. Hill CB, Yeh IT: Myoepithelial cell staining patterns of papillary breast lesions: from intraductal papillomas to invasive papillary carcinomas. Am J Clin Pathol; 2005 Jan;123(1):36-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myoepithelial cell staining patterns of papillary breast lesions: from intraductal papillomas to invasive papillary carcinomas.
  • We evaluated 25 intraductal papillomas and 18 papillary carcinomas (invasive, 4; micropapillary ductal carcinoma in situ [DCIS], 5; cases originally classified as intracystic/intraductal papillary carcinoma, 9) by calponin, smooth muscle myosin heavy chain (SMM-HC), and p63 immunostains.
  • Calponin, SMM-HC, and p63 labeled myoepithelial cells (MECs) in all intraductal papillomas and all micropapillary DCIS cases.
  • The invasive papillary carcinoma cases were uniformly negative for all stains.
  • The 9 cases originally diagnosed as intracystic/intraductal papillary carcinoma showed more variable results, with identification of an MEC layer in only 4 cases.
  • Of 9 cases originally classified as intraductal papillary carcinoma, 5 showed absence of a basal MEC layer by immunohistochemical analysis.
  • The lack of a basal MEC layer in these cases suggests a spectrum of progression from in situ to invasive disease and might help explain distant metastases from previously reported "intraductal papillary carcinoma. "
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Papillary / pathology. Papilloma, Intraductal / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15762278.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / DNA-Binding Proteins; 0 / Microfilament Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / calponin; EC 3.6.4.1 / Myosin Heavy Chains
  •  go-up   go-down


25. Ganesan S, Karthik G, Joshi M, Damodaran V: Ultrasound spectrum in intraductal papillary neoplasms of breast. Br J Radiol; 2006 Oct;79(946):843-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasound spectrum in intraductal papillary neoplasms of breast.
  • Intraductal papillary neoplasms (IPNs) of breast form a wide spectrum of pathological changes with benign intraductal papilloma occupying one end of the spectrum and papillary carcinoma at the other end.
  • Intraductal papillomas are known to occur anywhere within the ductal system and are broadly classified into central and peripheral types.
  • Intraductal papillary carcinoma is an uncommon ductal malignancy forming papillary structures, and these lesions characteristically lack the myoepithelial layer present in benign papillary neoplasms.
  • Three basic patterns of IPNs are recognized on ultrasound - intraductal mass with or without ductal dilatation, intracystic mass and a predominantly solid pattern with the intraductal mass totally filling the duct.
  • In an older age group, presence of a large solid component and evidence of spontaneous intracystic bleed are more suggestive of papillary carcinomas than benign papillomas.
  • We have serially studied 42 cases of intraductal papillary neoplasms with sonomammography and mammography from 2001 to 2004.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Papilloma, Intraductal / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16641415.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 13
  •  go-up   go-down


26. Shima Y, Yagi T, Inagaki M, Sadamori H, Tanaka N, Horimi T, Hamazaki S: Intraductal oncocytic papillary neoplasm of the pancreas with celiac artery compression syndrome and a jejunal artery aneurysm: report of a case. Surg Today; 2005;35(1):86-90
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal oncocytic papillary neoplasm of the pancreas with celiac artery compression syndrome and a jejunal artery aneurysm: report of a case.
  • We made a preoperative diagnosis of intraductal papillary adenocarcinoma of the pancreatic head and performed a laparotomy.
  • Microscopically, the tumor had papillary intracystic growth, and was lined by plump cells with abundant eosinophilic cytoplasm, consistent with a diagnosis of intraductal oncocytic papillary neoplasm.
  • We discuss this recently recognized entity of papillary neoplasm of the pancreas, and the importance of managing hepatic blood flow during pancreaticoduodenectomy in celiac artery compression syndrome.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Arterial Occlusive Diseases / radiography. Celiac Artery. Jejunum / blood supply. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15622472.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


27. Baumgaertner I, Corcos O, Couvelard A, Sauvanet A, Rebours V, Vullierme MP, Hentic O, Hammel P, Lévy P, Ruszniewski P: Prevalence of extrapancreatic cancers in patients with histologically proven intraductal papillary mucinous neoplasms of the pancreas: a case-control study. Am J Gastroenterol; 2008 Nov;103(11):2878-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of extrapancreatic cancers in patients with histologically proven intraductal papillary mucinous neoplasms of the pancreas: a case-control study.
  • BACKGROUND: Some studies have suggested that intraductal papillary mucinous neoplasms (IPMN) of the pancreas could be associated with extrapancreatic cancers (EPC)--especially from gastric and colorectal origin.
  • METHODS: N = 91, high-grade dysplasia/invasive cancer N = 87) with 356 age- and gender-matched controls.
  • The most frequent cancers in patients with IPMN and controls were: breast (30% in each group), prostate (10% and 13%, respectively, not significant [NS]), and colon/rectum (10 and 6%, respectively, NS).
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18853975.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Ichihara S, Fujimoto T, Hashimoto K, Moritani S, Hasegawa M, Yokoi T: Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast. Pathol Int; 2007 Mar;57(3):126-32
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast.
  • Papillary breast lesions remain a source of diagnostic confusion because the full range of epithelial proliferations may arise within, or secondarily involve, papilloma.
  • The expression of p63 and high-molecular-weight cytokeratins (HMWCK) was studied simultaneously in 33 papillary lesions including intraductal papilloma (IP, n = 10), atypical papilloma (AP, n = 8) and intraductal papillary carcinoma (IPC, n = 15) by double immunostaining.
  • The myoepithelial cell nuclei were stained dark brown whereas the cytoplasms of usual ductal hyperplasia (UDH) and myoepithelium were stained purple.
  • The myoepithelial layer was recognized as a dark brown dotted line at the epithelial stromal junction in all IP (10/10), most AP (7/8) and some IPC (7/15), suggesting that the retained myoepithelial layer in the papillary processes does not necessarily guarantee benignity.
  • These monotonous cells contrasted with the proliferating cells of UDH in papilloma, which had intense purple cytoplasm in a mosaic-like fashion.
  • The present data suggest that the double immunostaining with the two popular antibodies p63 and HMWCK is a useful tool for reproducible classification of papillary breast lesions.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Papillary / metabolism. DNA-Binding Proteins / metabolism. Keratins / metabolism. Mammary Glands, Human / metabolism. Papilloma, Intraductal / metabolism. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Female. Fluorescent Antibody Technique, Direct. Humans. Hyperplasia / metabolism. Hyperplasia / pathology. Immunoenzyme Techniques. Middle Aged. Molecular Weight. Retrospective Studies. Transcription Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17295644.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


29. Ding Y, Ruan Q: The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast. J Huazhong Univ Sci Technolog Med Sci; 2006;26(4):405-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast.
  • In order to explore the value of p63, smoothmuscle actin (alpha-SMA) and cytokeratin 5/6 (CK5/6) in the differential diagnosis of ductal lesions of breast, 88 tissue specimens of ductal lesions of breast were collected and examined histologically by HE staining.
  • The results showed that in 38 cases of benign breast lesions, the proliferating cells were all positive for p63 and alpha-SMA.
  • In 19 cases of ductal carcinoma in situ (DCIS) and 7 cases of intraductal papillary carcinoma, alpha-SMA positive cells formed a layer of continuous embroider-shaped structure and the p63 positive cells formed a layer of evenly separated embroider-shaped structure around the ducts.
  • In 38 cases of benign breast lesions, the positive rate of CK5/6 expression was 100%.
  • In 5 cases of atypical ductal hyperplasia, there were few positive cells in the ducts.
  • In 19 cases of invasive ductal carcinoma, almost no CK5/6 was detectable.
  • It was suggested that p63 could serve as a novel specific marker for the identification of breast myoepithelial cells.
  • CK5/6 is of value in differentiating ductal proliferation of varying degrees, especially in the differentiation between cancerous and non-cancerous changes.
  • Simultaneous detection of p63, CK5/6 and alpha-SMA can help increase the diagnostic accuracy of breast diseases.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Keratin-5 / biosynthesis. Keratin-6 / biosynthesis. Membrane Proteins / biosynthesis
  • [MeSH-minor] Breast Diseases / diagnosis. Breast Diseases / metabolism. Diagnosis, Differential. Female. Fibrocystic Breast Disease / diagnosis. Humans. Immunohistochemistry. Papilloma, Intraductal / diagnosis. Papilloma, Intraductal / metabolism. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17120733.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Keratin-5; 0 / Keratin-6; 0 / Membrane Proteins
  •  go-up   go-down


30. Chang SC, Liao JW, Wong ML, Lai YS, Liu CI: Mammary carcinoma with sebaceous differentiation in a dog. Vet Pathol; 2007 Jul;44(4):525-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammary carcinoma with sebaceous differentiation in a dog.
  • This report describes an invasive mammary carcinoma with a rare distinctive feature characterized by sebaceous differentiation of tumor cells.
  • This tumor occurred in a 10-year-old female mixed breed dog.
  • Microscopically, the tumors were composed of two distinctive neoplastic components, intraductal papillary adenocarcinoma and sebaceous carcinoma.
  • The cells with abundant foamy cytoplasm that resembled sebaceous cells were also found within the intraductal papillary-like nests of mammary carcinoma, providing evidence of sebaceous metaplasia.
  • Sebaceous differentiation in a mammary gland tumor is possible, because skin appendages and ductal apparatus of the mammary gland share a common anlagen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17606516.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Otsuki Y, Yamada M, Shimizu S, Suwa K, Yoshida M, Tanioka F, Ogawa H, Nasuno H, Serizawa A, Kobayashi H: Solid-papillary carcinoma of the breast: clinicopathological study of 20 cases. Pathol Int; 2007 Jul;57(7):421-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid-papillary carcinoma of the breast: clinicopathological study of 20 cases.
  • The purpose of the present paper was to evaluate the clinicopathological and biological features of 20 Japanese patients with solid-papillary carcinoma of the breast (SPC) or SPC associated with invasive breast cancer.
  • The incidence of SPC among all the breast cancers treated at two institutions was 1.1% and 1.7%, respectively.
  • Fifteen cases of SPC contained invasive cancers that ranged from <5% to 60% of the entire tumor area.
  • Histological types of invasive cancers were mucinous carcinoma in five cases and neuroendocrine cell carcinoma in 10 cases.
  • These results indicate that SPC is a potential precursor lesion for neuroendocrine carcinoma as well as mucinous carcinoma.
  • When all the cases were classified and analyzed according to both the 2002 tumor node metastasis (TNM) classification system and the Nottingham histological grade, SPC patients, even those with invasive cancers, seemed to have longer disease-free survival compared to patients with the other invasive breast cancers of matching grade and stage.
  • Clinicopathologically, SPC could be regarded as a separate type of ductal carcinoma in situ.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / chemistry. Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Neuroendocrine / chemistry. Carcinoma, Neuroendocrine / classification. Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / surgery. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasms, Multiple Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17587241.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


32. Reid-Lombardo KM, Mathis KL, Wood CM, Harmsen WS, Sarr MG: Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management. Ann Surg; 2010 Jan;251(1):64-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management.
  • OBJECTIVE: To estimate the frequency of extrapancreatic neoplasms in patients with IPMN compared with those with ductal pancreatic cancer and a general referral population.
  • Two control groups consisting of Group 1-patients with a diagnosis of ductal pancreatic adenocarcinoma (1:1) and Group 2-a general referral population (3:1) were matched for gender and age at diagnosis, year of registration, and residence.
  • The most common malignant neoplasms were nonmelanoma skin (n = 35), breast (n = 24), prostate (n = 24), colorectal cancers (n = 19), and carcinoid neoplasms (n = 6).
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Carcinoma, Pancreatic Ductal / therapy. Carcinoma, Papillary / therapy. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19858708.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1 UL1 RR024150
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


33. Sakai T, Tsuchiya S, Hama Y, Matsuyama I, Fujimori M: Can cytological findings predict intraductal spread of breast cancer? Histopathological case-control study. Pathol Int; 2005 Dec;55(12):775-80
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can cytological findings predict intraductal spread of breast cancer? Histopathological case-control study.
  • An important predictive factor for local recurrence after breast-conserving therapy is the state of the surgical margin.
  • In order to obtain a negative surgical margin, the present case-control study was conducted to determine whether the extent of ductal spread can be estimated from the information obtained by fine-needle aspiration (FNA).
  • Samples from 69 cases of extensive ductal spread (EDS) in which it was thought that cancer cells had remained in the residual breast when the lumpectomy was performed with 2 cm margins, were retrieved and compared with 62 cases having almost the same clinical and pathological tumor size.
  • The cases of EDS included a significantly larger number of papillotubular carcinomas (37%vs 13%, P = 0.004) and displayed a high nuclear atypia (42%vs 26%, P = 0.001).
  • Cancer cells with cohesive papillary-like clusters suggesting papillotubular carcinoma and with a large nuclear diameter were significantly more numerous in cases of EDS (P < 0.01).
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16287492.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


34. Sohn WJ, Jo S: A huge intraductal papillary mucinous carcinoma of the bile duct treated by right trisectionectomy with caudate lobectomy. World J Surg Oncol; 2009;7:93
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A huge intraductal papillary mucinous carcinoma of the bile duct treated by right trisectionectomy with caudate lobectomy.
  • BACKGROUND: Because intraductal papillary mucinous neoplasm of the bile duct (IPMN-B) is believed to show a better clinical course than non-papillary biliary neoplasms, it is important to make a precise diagnosis and to perform complete surgical resection.
  • Radiologic images showed marked dilatation of the left medial sectional bile duct (B4) resulting in a bulky cystic mass with multiple internal papillary projections.
  • The histopathological examination yielded the diagnosis of mucin-producing oncocytic intraductal papillary carcinoma of the bile duct with poorly differentiated carcinomas showing neuroendocrine differentiation.
  • CONCLUSION: Considering a favorable prognosis of IPMN-B compared to non-papillary biliary neoplasms, this tumor can be a good indication for aggressive surgical resection regardless of its tumor size.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Extrahepatic / surgery. Carcinoma, Intraductal, Noninfiltrating / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2000 Jan;31(1):12-7 [10613721.001]
  • [Cites] Chin Med J (Engl). 2008 Dec 20;121(24):2610-2 [19187604.001]
  • [Cites] Hepatology. 2001 Oct;34(4 Pt 1):651-8 [11584359.001]
  • [Cites] Mod Pathol. 2001 Dec;14(12):1304-9 [11743055.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2180-7 [12412172.001]
  • [Cites] Br J Surg. 2004 Jan;91(1):99-104 [14716802.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):783-93 [14770435.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):327-38 [15104295.001]
  • [Cites] Ann Surg. 1998 Jan;227(1):63-9 [9445112.001]
  • [Cites] Hepatology. 2005 Sep;42(3):657-64 [16116640.001]
  • [Cites] J Hepatol. 2006 Feb;44(2):350-8 [16360234.001]
  • [Cites] J Hepatol. 2006 Feb;44(2):249-50 [16360969.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):248-53 [16858187.001]
  • [Cites] Hepatology. 2006 Nov;44(5):1333-43 [17058219.001]
  • [Cites] Ann Diagn Pathol. 2007 Feb;11(1):34-8 [17240305.001]
  • [Cites] Histol Histopathol. 2008 Jan;23(1):41-50 [17952856.001]
  • [Cites] J Surg Oncol. 2008 May 1;97(6):508-12 [18314868.001]
  • [Cites] Ann Hepatol. 2008 Apr-Jun;7(2):168-73 [18626437.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(6):542-50 [11180885.001]
  • (PMID = 19961613.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2797779
  •  go-up   go-down


35. Fukushima N, Fukayama M: Mucinous cystic neoplasms of the pancreas: pathology and molecular genetics. J Hepatobiliary Pancreat Surg; 2007;14(3):238-42
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is clearly distinguished from ductal adenocarcinoma and intraductal papillary mucinous neoplasm (IPMN).
  • However, MCN can progress to infiltrating carcinoma, and frequently shows a similar histological pattern to ductal adenocarcinoma.
  • Several genetic alterations such as K-ras oncogene mutation, and epigenetic alterations such as hypermethylation of p16 in the invasive component of MCN are also common with ductal adenocarcinoma.
  • It is important to diagnose the lesions before they progress to an invasive carcinoma.
  • MCN is one of the precursors of invasive pancreatic carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous. Biomarkers, Tumor / genetics. DNA, Neoplasm / genetics. Pancreatic Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520198.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Number-of-references] 24
  •  go-up   go-down


36. Olu-Eddo AN, Ohanaka CE: Intracystic papillary carcinoma of the breast in a Nigerian male: case report. Niger Postgrad Med J; 2008 Dec;15(4):270-1
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracystic papillary carcinoma of the breast in a Nigerian male: case report.
  • Intracystic papillary non invasive breast carcinoma is an extremely rare form of intraductal carcinoma constituting 5% of male breast cancer.
  • The latter accounts for only 1% of all breast cancers.
  • This may be the first case of intracystic papillary carcinoma of the breast in the Nigerian male.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Papillary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169348.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


37. Jin DY, Lou WH, Wang DS, Kuang TT: [Clinical evaluation of 21 cases of total pancreatectomy]. Zhonghua Wai Ke Za Zhi; 2007 Jan 1;45(1):21-3
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median survival of tubular adenocarcinoma and intraductal papillary mucinous neoplasms of the pancreas (IPMNs) were 7 months (1.2 - 9.0 months) and 11.3 months (10.0 - 13.0 months), respectively.
  • It's an operation of choice for IPMNs, but with pancreatic carcinoma, the warranty of operation should be considered.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403283.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


38. Edge MD, Hoteit M, Patel AP, Wang X, Baumgarten DA, Cai Q: Clinical significance of main pancreatic duct dilation on computed tomography: single and double duct dilation. World J Gastroenterol; 2007 Mar 21;13(11):1701-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with single duct dilation, especially such patients without any evidence of chronic pancreatitis, also need careful follow-up since the possibility of pancreatic malignancy, including adenocarcinoma and intraductal papillary mucinous tumors, is still high.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2000 Jul;52(1):74-7 [10882966.001]
  • [Cites] Arch Surg. 1999 Sep;134(9):1002-7 [10487597.001]
  • [Cites] Abdom Imaging. 2003 May-Jun;28(3):357-65 [12719906.001]
  • [Cites] Gastroenterology. 1972 Aug;63(2):217-26 [5048325.001]
  • [Cites] Gut. 1972 Dec;13(12):1014-25 [4568802.001]
  • [Cites] Radiology. 1976 Feb;118(2):295-300 [1250961.001]
  • [Cites] Radiology. 1976 May;119(2):271-4 [1265253.001]
  • [Cites] N Engl J Med. 1977 Oct 6;297(14):737-42 [895803.001]
  • [Cites] Arch Surg. 1982 Aug;117(8):1058-61 [7103724.001]
  • [Cites] Gastrointest Endosc. 1989 May-Jun;35(3):210-3 [2759399.001]
  • [Cites] Hepatogastroenterology. 1993 Feb;40(1):52-5 [8462930.001]
  • [Cites] Endoscopy. 1993 Sep;25(7):489-90 [8261999.001]
  • [Cites] Ital J Gastroenterol. 1996 Feb-Mar;28(2):63-9 [8781996.001]
  • [Cites] Am J Surg. 1998 Mar;175(3):203-8 [9560120.001]
  • [Cites] Nihon Rinsho. 1998 Nov;56(11):2874-9 [9847613.001]
  • [Cites] Nihon Rinsho. 1998 Nov;56(11):2885-9 [9847615.001]
  • [Cites] Jpn J Clin Oncol. 2002 Oct;32(10):407-11 [12451037.001]
  • (PMID = 17461473.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4146949
  •  go-up   go-down


39. Schönleben F, Qiu W, Allendorf JD, Chabot JA, Remotti HE, Su GH: Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas. J Gastrointest Surg; 2009 Aug;13(8):1510-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas.
  • BACKGROUND: Mutations of KRAS are known to occur in periampullary and ampullary adenomas and carcinomas.
  • While oncogenic BRAF contributes to the tumorigenesis of both pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasms/carcinomas (IPMN/IPMC), PIK3CA mutations were only detected in IPMN/IPMC.
  • This study aimed to elucidate possible roles of BRAF and PIK3CA in the development of ampullary and periampullary adenomas and carcinomas.
  • METHODS: Mutations of BRAF, NRAS, HRAS, KRAS, and PIK3CA were evaluated in seven adenomas, seven adenomas with carcinoma in situ, and 21 adenocarcinomas of the periampullary duodenal region and the ampulla of Vater.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2756-60 [7796400.001]
  • [Cites] Oncogene. 1995 May 4;10(9):1875-8 [7753564.001]
  • [Cites] J Clin Pathol. 1996 Jun;49(6):460-4 [8763258.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1731-4 [9135016.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2140-3 [9187111.001]
  • [Cites] FEBS Lett. 1997 Jun 23;410(1):91-5 [9247130.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):129-33 [9815548.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7678-81 [15520168.001]
  • [Cites] Cancer Biol Ther. 2004 Aug;3(8):772-5 [15254419.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1477-80 [15608678.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1441-6 [16533766.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3851-5 [16778113.001]
  • [Cites] Cancer Lett. 2007 Jan 8;245(1-2):163-70 [16478646.001]
  • [Cites] Exp Cell Res. 1999 Nov 25;253(1):34-46 [10579909.001]
  • [Cites] World J Surg. 2000 Jan;24(1):54-9 [10594204.001]
  • [Cites] Biochem J. 2000 Mar 15;346 Pt 3:561-76 [10698680.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1821-5 [10854204.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Surg Clin North Am. 2001 Jun;81(3):543-55 [11459270.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:615-75 [11687500.001]
  • [Cites] Biol Cell. 2001 Sep;93(1-2):53-62 [11730323.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7420-5 [12032298.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Nature. 2002 Aug 29;418(6901):934 [12198537.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6451-5 [12438234.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6997-7000 [12460918.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7001-3 [12460919.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):19-20 [12447372.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):1983-93 [12612072.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):272-8 [12640108.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1684-95 [12670923.001]
  • [Cites] Cancer Lett. 2003 Sep 25;199(2):169-73 [12969789.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1255-60 [14507635.001]
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5048-50 [15289301.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):313-9 [15488754.001]
  • [Cites] Hum Pathol. 1985 Mar;16(3):305-10 [3972407.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • (PMID = 19440799.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109525-05; United States / NCI NIH HHS / CA / R21 CA127701; United States / NCI NIH HHS / CA / CA127701-01A2; United States / NCI NIH HHS / CA / R01CA109525; United States / NCI NIH HHS / CA / R01 CA109525; United States / NCI NIH HHS / CA / CA109525-05; United States / NCI NIH HHS / CA / R21 CA127701-01A2; United States / NCI NIH HHS / CA / R21CA127701
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS164917; NLM/ PMC3915027
  •  go-up   go-down


40. Uesato M, Nabeya Y, Miyazaki S, Aoki T, Akai T, Shuto K, Tanizawa T, Miyazaki M, Matsubara H: Postoperative recurrence of an IPMN of the pancreas with a fistula to the stomach. World J Gastrointest Endosc; 2010 Oct 16;2(10):349-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on a case of a 74 year old man who was diagnosed with a recurrence of non-invasive carcinoma of intraductal papillary mucinous neoplasm (non-invasive IPMN) by postoperative gastroscopy (GS).
  • A histopathological study revealed non-invasive adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160585.001).
  • [ISSN] 1948-5190
  • [Journal-full-title] World journal of gastrointestinal endoscopy
  • [ISO-abbreviation] World J Gastrointest Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999103
  • [Keywords] NOTNLM ; Endoscopy / Fistula / Intraductal papillary mucinous neoplasm / Recurrence / Stomach
  •  go-up   go-down


41. Ohuchida K, Mizumoto K, Yu J, Yamaguchi H, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M: S100A6 is increased in a stepwise manner during pancreatic carcinogenesis: clinical value of expression analysis in 98 pancreatic juice samples. Cancer Epidemiol Biomarkers Prev; 2007 Apr;16(4):649-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S100A6 is increased in a stepwise manner during pancreatic carcinogenesis: clinical value of expression analysis in 98 pancreatic juice samples.
  • Microdissected invasive ductal carcinoma and intraductal papillary mucinous neoplasm (IPMN) cells expressed significantly higher levels of S100A6 than did microdissected pancreatitis-affected epithelial and normal cells (all comparison; P < 0.008).
  • Median levels of S100A6 in invasive ductal carcinoma were higher than those in IPMN, and those in pancreatitis-affected epithelial cells tended to be higher than those in normal cells, although these differences were not statistically significant.
  • The present data suggest that expression of S100A6 is increased in a stepwise manner during pancreatic carcinogenesis and may be a biomarker for evaluating malignant potential.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416753.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / RNA, Neoplasm; 0 / S100 Proteins; 105504-00-5 / S100A6 protein, human
  •  go-up   go-down


42. Chang JM, Moon WK, Cho N, Han W, Noh DY, Park IA, Jung EJ: Risk of carcinoma after subsequent excision of benign papilloma initially diagnosed with an ultrasound (US)-guided 14-gauge core needle biopsy: a prospective observational study. Eur Radiol; 2010 May;20(5):1093-100
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of carcinoma after subsequent excision of benign papilloma initially diagnosed with an ultrasound (US)-guided 14-gauge core needle biopsy: a prospective observational study.
  • RESULTS: Of the 114 patients, 87 eventually underwent surgery: among the 100 supposed benign papillomas, surgical excision revealed fibrocystic change or no residual lesion in nine cases, intraductal papilloma in 74, atypical papilloma in 13, papillary ductal carcinoma in situ (DCIS) in three and one invasive papillary carcinoma.
  • The upgrade rate for an atypical papilloma or papilloma with adjacent foci of atypical ductal hyperplasia (ADH) and malignancy was 13% (95% CI = 7.1-21.2%) and 4% (95% CI = 1.1-9.9%), respectively.
  • CONCLUSION: Surgical excision should be considered for benign intraductal papillomas above 1.5 cm in size.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Papillary / pathology. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19890638.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


43. Romics L Jr, O'Brien ME, Relihan N, O'Connell F, Redmond HP: Intracystic papillary carcinoma in a male as a rare presentation of breast cancer: a case report and literature review. J Med Case Rep; 2009;3:13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracystic papillary carcinoma in a male as a rare presentation of breast cancer: a case report and literature review.
  • INTRODUCTION: The term "intracystic papillary ductal carcinoma in situ" has recently changed and is now more appropriately referred to "intracystic papillary carcinoma".
  • Intracystic papillary carcinoma in men is an extremely rare disease with only a few case presentations published in the literature so far.
  • CASE PRESENTATION: We discuss a case of a 44-year-old Caucasian man with an intracystic papillary carcinoma treated with simple mastectomy, sentinel lymph-node biopsy and contralateral risk-reducing mastectomy.
  • These were followed by adjuvant radiotherapy of the breast.
  • CONCLUSION: Triple assessment (i.e. clinical examination and radiological and histological assessment) with a high level of clinical suspicion is necessary to diagnose intracystic papillary carcinoma in men due to its rarity.
  • Furthermore, genetic testing and risk-reducing mastectomy should also be considered in cases of a strong family history for male breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2005 Jan;123(1):36-44 [15762278.001]
  • [Cites] Breast. 2005 Aug;14(4):322-4 [16085239.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1733-41 [16138363.001]
  • [Cites] Lancet. 2006 Feb 18;367(9510):595-604 [16488803.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):1002-7 [16861972.001]
  • [Cites] Br J Radiol. 2006 Oct;79(946):843-9 [16641415.001]
  • [Cites] Ann R Coll Surg Engl. 2006 Sep;88(5):W3-5 [17002839.001]
  • [Cites] Am J Surg. 2007 Oct;194(4):497-500 [17826064.001]
  • [Cites] J Postgrad Med. 2008 Jan-Mar;54(1):39-40 [18296806.001]
  • [Cites] Cancer. 2008 Sep 1;113(5):916-20 [18661510.001]
  • [Cites] Breast J. 2003 May-Jun;9(3):249-50 [12752638.001]
  • [Cites] Diagn Cytopathol. 2003 Jan;28(1):39-44 [12508181.001]
  • [Cites] Am J Surg. 2002 Oct;184(4):364-8 [12383904.001]
  • [Cites] Eur Radiol. 2002 Sep;12(9):2207-10 [12195471.001]
  • [Cites] Hum Pathol. 1994 Aug;25(8):802-9 [8056421.001]
  • (PMID = 19144122.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2635376
  •  go-up   go-down


44. Toll AD, Bibbo M: Identification of gastrointestinal contamination in endoscopic ultrasound-guided pancreatic fine needle aspiration. Acta Cytol; 2010 May-Jun;54(3):245-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate whether B72.3 and CEA could identify duodenal and gastric contamination in cell blocks of clinically proven cases of pancreatic ductal carcinoma, intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasm (MCN).
  • STUDY DESIGN: Cell blocks of pancreatic fine needle aspirates from 19 ductal adenocarcinomas, 9 IPMNs, 5 MCNs, and 22 cases containing gastrointestinal epithelial contamination (GIC) (7 gastric, 15 duodenal) were stained with antibody to carcinoembryonic antigen (CEA) and B72.3.
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / metabolism. Antibodies, Neoplasm / metabolism. Artifacts. Biomarkers / metabolism. Biopsy, Fine-Needle. Carcinoembryonic Antigen / metabolism. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / metabolism. Diagnostic Errors / prevention & control. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518405.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / B72.3 antibody; 0 / Biomarkers; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


45. Körner M, Hayes GM, Rehmann R, Zimmermann A, Friess H, Miller LJ, Reubi JC: Secretin receptors in normal and diseased human pancreas: marked reduction of receptor binding in ductal neoplasia. Am J Pathol; 2005 Oct;167(4):959-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretin receptors in normal and diseased human pancreas: marked reduction of receptor binding in ductal neoplasia.
  • We investigated 58 non-neoplastic pancreases and 55 pancreatic tumors for receptor localization and density by in vitro receptor autoradiography using [(125)I]Tyr(10) rat secretin and for secretin receptor mRNA by reverse transcriptase-polymerase chain reaction.
  • Secretin receptors were highly expressed in non-neoplastic ducts and lobuli and also in lower amounts in ductal neoplasias, including ductal adenocarcinoma, intraductal papillary mucinous tumors, and pancreatic intraepithelial neoplasia.
  • Reverse transcriptase-polymerase chain reaction revealed wild-type receptor mRNA in the non-neoplastic pancreas and both wild-type and spliced variant receptor transcripts in ductal adenocarcinomas.
  • This study is the first to describe the precise secretin receptor distribution in human non-neoplastic pancreas and various pancreatic tumors.
  • High secretin receptor expression in the non-neoplastic ducts reflects the major role of secretin in bicarbonate secretion.
  • Reduced secretin binding in pancreatic ductal tumors may relate to (alternatively spliced) secretin receptor isoforms.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / metabolism. Pancreas / metabolism. Pancreatic Neoplasms / metabolism. Receptors, G-Protein-Coupled / metabolism. Receptors, Gastrointestinal Hormone / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Alternative Splicing. Animals. Autoradiography. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Humans. Iodine Radioisotopes. Pancreatic Ducts / metabolism. RNA, Messenger / genetics. Rats

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1998 Mar;184(3):234-9 [9614373.001]
  • [Cites] Gastroenterology. 1998 Feb;114(2):382-97 [9453500.001]
  • [Cites] Am J Physiol. 1998 Dec;275(6 Pt 1):G1437-44 [9843782.001]
  • [Cites] Endocrine. 1998 Oct;9(2):171-83 [9867251.001]
  • [Cites] Am J Physiol. 1999 Aug;277(2 Pt 1):G487-94 [10444464.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):3105-12 [10850463.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Dig Dis. 2001;19(1):15-23 [11385247.001]
  • [Cites] J Membr Biol. 2001 Sep 15;183(2):71-84 [11562789.001]
  • [Cites] Genome Biol. 2001;2(12):REVIEWS3013 [11790261.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):500-11 [11832464.001]
  • [Cites] J Nucl Med. 2002 May;43(5):610-6 [11994522.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5223-9 [12234988.001]
  • [Cites] Pharmacol Rev. 2003 Mar;55(1):167-94 [12615957.001]
  • [Cites] Endocr Rev. 2003 Aug;24(4):389-427 [12920149.001]
  • [Cites] J Nucl Med. 2003 Oct;44(10):1649-54 [14530481.001]
  • [Cites] J Gastroenterol. 2003;38(11):1025-35 [14673718.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Biochem Biophys Res Commun. 1981 Oct 30;102(4):1336-41 [6274336.001]
  • [Cites] J Histochem Cytochem. 1982 Sep;30(9):864-73 [6813372.001]
  • [Cites] Am J Physiol. 1984 Jun;246(6 Pt 1):G710-7 [6204536.001]
  • [Cites] Cell Tissue Res. 1985;242(3):633-9 [2416452.001]
  • [Cites] Peptides. 1987 Jul-Aug;8(4):633-7 [2819833.001]
  • [Cites] Pancreas. 1988;3(5):529-35 [3186683.001]
  • [Cites] Gastroenterology. 1989 Jun;96(6):1439-44 [2565843.001]
  • [Cites] Ann Intern Med. 1989 Nov 1;111(9):713-22 [2572194.001]
  • [Cites] Int J Pancreatol. 1989 Sep;5(2):191-201 [2600453.001]
  • [Cites] Gastroenterology. 1990 Jun;98(6):1666-74 [2186957.001]
  • [Cites] J Biol Chem. 1991 Jan 5;266(1):316-22 [1702423.001]
  • [Cites] EMBO J. 1991 Jul;10(7):1635-41 [1646711.001]
  • [Cites] Am J Physiol. 1993 Nov;265(5 Pt 1):G805-10 [8238510.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Feb 27;207(3):883-90 [7864894.001]
  • [Cites] Mol Pharmacol. 1995 Mar;47(3):467-73 [7700244.001]
  • [Cites] Ann Intern Med. 1996 Jul 1;125(1):26-34 [8644985.001]
  • [Cites] Br J Cancer. 1997;75(10):1467-73 [9166939.001]
  • [Cites] Gut. 1998 Apr;42(4):546-50 [9616318.001]
  • (PMID = 16192632.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / RNA, Messenger; 0 / Receptors, G-Protein-Coupled; 0 / Receptors, Gastrointestinal Hormone; 0 / secretin receptor
  • [Other-IDs] NLM/ PMC1603664
  •  go-up   go-down


46. Zhai J, Sarkar R, Ylagan L: Pancreatic mucinous lesions: a retrospective analysis with cytohistological correlation. Diagn Cytopathol; 2006 Nov;34(11):724-30
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis of mucinous pancreatic lesions, which include mucinous noncystic adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), mucinous cystic neoplasm (MCN), and mucinous metaplasia, is critical, given different clinical management and prognosis.
  • This retrospective study is done to assess the cytological features and pitfalls associated with these entities in cytological samples.A search for pancreatic cytology specimens with histological confirmation of the various pancreatic mucinous lesions was done from 1988 to 2005: 9 mucinous adenocarcinoma, 14 IPMN, 11 MCN, and 3 mucinous metaplasia.
  • Of the 22 cytological features evaluated, the presence of three-dimensional clusters, micropapillary structures, and nuclear atypia, which includes nuclear crowding, increased N/C ratio, anisonucleosis, nuclear membrane contour irregularity, clumpy chromatin, and prominent nucleoli, was found to be consistently associated with mucinous adenocarcinoma.
  • The cytological diagnosis of mucinous pancreatic lesions remains challenging, except for mucinous noncystic adenocarcinoma.
  • False-positive diagnosis of adenocarcinoma occurs not infrequently in the setting of IPMN with severe dysplastic epithelial change and in lesions with associated acute inflammation, and can be a pitfall in the diagnosis of these lesions.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17041953.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Nobili C, Franciosi C, Degrate L, Caprotti R, Romano F, Perego E, Trezzi R, Leone BE, Uggeri F: A case of pancreatic heterotopy of duodenal wall, intraductal papillary mucinous tumor and intraepithelial neoplasm of pancreas, papillary carcinoma of kidney in a single patient. Tumori; 2006 Sep-Oct;92(5):455-8
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of pancreatic heterotopy of duodenal wall, intraductal papillary mucinous tumor and intraepithelial neoplasm of pancreas, papillary carcinoma of kidney in a single patient.
  • We report a case of the contemporaneous presence of two histologically different pancreatic neoplasms, one renal cancer and one embryogenic duodenal anomaly in a single patient.
  • Histopathologic analysis of the surgical specimen revealed mild differentiated papillary renal carcinoma, intraductal papillary mucinous adenoma of the pancreatic head, foci of intraepithelial pancreatic neoplasm and pancreatic heterotopy of duodenal muscular and submucosal layers.
  • [MeSH-major] Carcinoma, Pancreatic Ductal. Carcinoma, Papillary. Choristoma. Cystadenocarcinoma, Mucinous. Duodenal Diseases. Kidney Neoplasms. Neoplasms, Multiple Primary. Pancreas. Pancreatic Neoplasms
  • [MeSH-minor] Aged. Carcinoma, Renal Cell / diagnosis. Humans. Magnetic Resonance Imaging. Male. Nephrectomy / methods. Pancreaticoduodenectomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168444.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


48. Obenauer S, Sohns C, Werner C, Grabbe E: Impact of breast density on computer-aided detection in full-field digital mammography. J Digit Imaging; 2006 Sep;19(3):258-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of breast density on computer-aided detection in full-field digital mammography.
  • The goal of this study was to evaluate the performance of a computer-aided detection (CAD) system in full-field digital mammography (Senographe 2000D, General Electric, Buc, France) in finding out carcinomas depending on the parenchymal density.
  • A total of 226 mediolateral oblique (MLO) and 186 craniocaudal (CC) mammographic views of histologically proven cancers were retrospectively evaluated with a digital CAD system (ImageChecker V2.3 R2 Technology, Los Altos, CA, USA).
  • In conclusion, there seems to be a tendency for breast tissue density to affect the detection rate of breast cancer when using the CAD system.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Breast Neoplasms / pathology. Breast Neoplasms / radiography. Mammography. Radiographic Image Enhancement. Radiographic Image Interpretation, Computer-Assisted
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radiography. Calcinosis / pathology. Calcinosis / radiography. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / radiography. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / radiography. Carcinoma, Lobular / pathology. Carcinoma, Lobular / radiography. Carcinoma, Medullary / pathology. Carcinoma, Medullary / radiography. Carcinoma, Papillary / pathology. Carcinoma, Papillary / radiography. False Positive Reactions. Female. Germany. Hemangiosarcoma / pathology. Hemangiosarcoma / radiography. Humans. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2001 Apr;219(1):192-202 [11274556.001]
  • [Cites] Rofo. 2000 Dec;172(12):957-64 [11199437.001]
  • [Cites] Eur Radiol. 2001;11(12):2454-9 [11734939.001]
  • [Cites] Eur Radiol. 2002 Jul;12(7):1697-702 [12111060.001]
  • [Cites] Eur Radiol. 2002 Dec;12(12):3015-7 [12439584.001]
  • [Cites] Clin Radiol. 2003 Feb;58(2):133-6 [12623042.001]
  • [Cites] AJR Am J Roentgenol. 2003 Sep;181(3):687-93 [12933460.001]
  • [Cites] AJR Am J Roentgenol. 2003 Oct;181(4):1083-8 [14500236.001]
  • [Cites] CA Cancer J Clin. 1983 Jan-Feb;33(1):26-39 [6401574.001]
  • [Cites] Invest Radiol. 1990 Oct;25(10):1102-10 [2079409.001]
  • [Cites] Radiology. 1994 Apr;191(1):241-4 [8134580.001]
  • [Cites] Radiology. 1994 May;191(2):315-7 [8153298.001]
  • [Cites] Sci Am. 1996 Sep;275(3):56-9 [8701294.001]
  • [Cites] Acad Radiol. 1995 Aug;2(8):655-62 [9419620.001]
  • [Cites] Eur J Radiol. 1999 Jul;31(1):25-34 [10477095.001]
  • [Cites] Radiology. 1999 Sep;212(3):817-27 [10478252.001]
  • [Cites] AJR Am J Roentgenol. 2005 Feb;184(2):439-44 [15671360.001]
  • [Cites] J Digit Imaging. 2005 Sep;18(3):227-33 [15827823.001]
  • [Cites] Eur J Radiol. 1999 Aug;31(2):97-109 [10565509.001]
  • [Cites] Radiology. 2000 May;215(2):554-62 [10796939.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 5;92(13):1081-7 [10880551.001]
  • [Cites] Rofo. 2001 Mar;173(3):218-23 [11293863.001]
  • (PMID = 16741664.001).
  • [ISSN] 0897-1889
  • [Journal-full-title] Journal of digital imaging
  • [ISO-abbreviation] J Digit Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3045151
  •  go-up   go-down


49. Mercado CL, Hamele-Bena D, Oken SM, Singer CI, Cangiarella J: Papillary lesions of the breast at percutaneous core-needle biopsy. Radiology; 2006 Mar;238(3):801-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary lesions of the breast at percutaneous core-needle biopsy.
  • PURPOSE: To retrospectively review the imaging and histologic findings in patients in whom a benign papillary lesion was diagnosed at core-needle breast biopsy.
  • The authors reviewed the findings from 42 patients (age range, 26-76 years; mean age, 54.3 years) with 43 benign papillary lesions diagnosed at core-needle biopsy.
  • RESULTS: At core-needle biopsy, lesions were diagnosed as papilloma (n = 29), sclerosing papilloma (n = 8), and benign papillary lesions not otherwise specified (n = 6).
  • For the 36 lesions that were surgically excised, histologic follow-up showed no residual lesion in 10, intraductal papilloma in 14, intraductal papillomatosis in two, papilloma with adjacent foci of atypical ductal hyperplasia (ADH) in eight, and well-differentiated papillary ductal carcinoma in situ (DCIS) in two.
  • In nine of the 42 patients (21%), the diagnosis was upgraded to either ADH or DCIS (exact two-sided 95% CI = 11.4%, 36.4%).
  • CONCLUSION: The results strongly suggest that papillary lesions diagnosed as benign at core-needle biopsy should be surgically excised because a substantial number of lesions were upgraded to ADH and DCIS at excision.
  • [MeSH-major] Biopsy, Needle. Breast / pathology. Breast Neoplasms / pathology. Papilloma / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2006.
  • [CommentIn] Radiology. 2007 Apr;243(1):300-1; author reply 301 [17392265.001]
  • (PMID = 16424237.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Matsuura K, Yamaguchi Y, Osaki A, Ohara M, Okita R, Emi A, Murakami S, Arihiro K: FOXP3 expression of micrometastasis-positive sentinel nodes in breast cancer patients. Oncol Rep; 2009 Nov;22(5):1181-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FOXP3 expression of micrometastasis-positive sentinel nodes in breast cancer patients.
  • In the present study, we attempted to clarify the immunological status of SNs with or without micrometastasis in breast cancer patients.
  • Of the 71 metastasis-negative SNs, 11 showed positive bands on RT-PCR specific for mamma-globin [pN0(mol+)].
  • In patients with breast cancer, micrometastasis can stimulate Th1 response in SNs.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Papillary / genetics. Forkhead Transcription Factors / genetics. Gene Expression Regulation, Neoplastic / physiology. Lymph Nodes / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787238.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / GATA3 Transcription Factor; 0 / GATA3 protein, human; 0 / RNA, Messenger; 0 / T-Box Domain Proteins; 0 / T-box transcription factor TBX21
  •  go-up   go-down


51. Li CI, Uribe DJ, Daling JR: Clinical characteristics of different histologic types of breast cancer. Br J Cancer; 2005 Oct 31;93(9):1046-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of different histologic types of breast cancer.
  • Breast cancer is a heterogeneous disease, though little is known about some of its rarer forms, including certain histologic types.
  • Using Surveillance, Epidemiology, and End Results Program data on 135 157 invasive breast cancer cases diagnosed from 1992 to 2001, relationships between nine histologic types of breast cancer and various tumour characteristics were assessed.
  • Among women aged 50-89 years at diagnosis, lobular and ductal/lobular carcinoma cases were more likely to be diagnosed with stage III/IV, > or =5.0 cm, and node-positive tumours compared to ductal carcinoma cases.
  • Mucinous, comedo, tubular, and medullary carcinomas were less likely to present at an advanced stage.
  • Lobular, ductal/lobular, mucinous, tubular, and papillary carcinomas were less likely, and comedo, medullary, and inflammatory carcinomas were more likely to be oestrogen receptor (ER) negative/progesterone receptor (PR) negative and high grade (notably, 68.2% of medullary carcinomas were ER-/PR- vs 19.3% of ductal carcinomas).
  • Inflammatory carcinomas are associated with more aggressive tumour phenotypes, and mucinous, tubular, and papillary tumours are associated with less aggressive phenotypes.
  • The histologic types of breast cancer studied here differ greatly in their clinical presentations, and the differences in their hormone receptor profiles and grades point to their likely different aetiologies.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Papillary / pathology. Neoplasms, Ductal, Lobular, and Medullary / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1993 Jul;218(1):13-21 [8328824.001]
  • [Cites] JAMA. 2003 Mar 19;289(11):1421-4 [12636465.001]
  • [Cites] Arch Surg. 1979 Apr;114(4):485-8 [435063.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2254-9 [12805323.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2570-7 [10861435.001]
  • [Cites] JAMA. 2003 Jun 25;289(24):3254-63 [12824206.001]
  • [Cites] Natl Cancer Inst Monogr. 1981 Jun;(57):1-1082 [7278951.001]
  • [Cites] Breast Cancer Res Treat. 2004 May;85(1):23-9 [15039595.001]
  • [Cites] Int J Epidemiol. 1992 Apr;21(2):222-8 [1428473.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1128-35 [15247123.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1175-81 [14652277.001]
  • [Cites] Breast. 2000 Oct;9(5):267-70; discussion 270 [14732176.001]
  • [Cites] JAMA. 2002 Feb 13;287(6):734-41 [11851540.001]
  • [Cites] Histopathology. 1982 Mar;6(2):149-61 [7076138.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):1-7 [8478135.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):549-59; discussion 559-61 [7574934.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):342-51 [14746851.001]
  • [Cites] Arch Intern Med. 2003 Oct 13;163(18):2149-53 [14557212.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):593-600 [12101105.001]
  • [Cites] Cancer Causes Control. 2003 Apr;14(3):225-33 [12814201.001]
  • [Cites] Breast Cancer Res. 2004;6(3):R149-56 [15084238.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1673-7 [8156495.001]
  • (PMID = 16175185.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U54 CA132383; United States / NCI NIH HHS / CA / U56 CA096286; United States / NCI NIH HHS / CA / U56 CA096288
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ PMC2361680
  •  go-up   go-down


52. Wechselberger C, Strizzi L, Kenney N, Hirota M, Sun Y, Ebert A, Orozco O, Bianco C, Khan NI, Wallace-Jones B, Normanno N, Adkins H, Sanicola M, Salomon DS: Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma. Oncogene; 2005 Jun 9;24(25):4094-105
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma.
  • Human Cripto-1 (CR-1) is overexpressed in approximately 80% of human breast, colon and lung carcinomas.
  • Mouse Cr-1 upregulation is also observed in a number of transgenic (Tg) mouse mammary tumors.
  • Virgin female MMTV/CR-1 Tg mice exhibited enhanced ductal branching, dilated ducts, intraductal hyperplasia, hyperplastic alveolar nodules and condensation of the mammary stroma.
  • In the highest CR-1-expressing subline, G4, 38% (12/31) of the multiparous animals aged 12-20 months developed hyperplasias and approximately 33% (11/31) developed papillary adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Epidermal Growth Factor / genetics. Mammary Glands, Animal / pathology. Mammary Neoplasms, Animal / genetics. Membrane Glycoproteins / genetics. Neoplasm Proteins / genetics

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897912.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Complementary; 0 / GPI-Linked Proteins; 0 / Growth Substances; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / TDGF1 protein, human; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


53. Popnikolov NK, Cavone SM, Schultz PM, Garcia FU: Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells. Mod Pathol; 2005 Dec;18(12):1535-41
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
  • We evaluated the low affinity neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
  • Immunohistochemical staining for p75NTR was performed on paraffin sections of 122 malignant breast lesions, 28 benign lesions and the adjacent normal breast tissue.
  • The staining pattern was compared to those of myosin heavy chain and p63. p75NTR immunostain was consistently positive and compatible with p63 and myosin immunoreactivity in the myoepithelial cells of the normal mammary gland, benign breast lesions (six usual ductal hyperplasias, six specimens with sclerosing adenosis, eight intraductal papillomas, six fibroadenomas), and carcinoma in situ (18 ductal carcinomas in situ, two noninvasive papillary carcinomas, two lobular carcinomas in situ).
  • The luminal cells were negative for p75NTR, but rare positive cells were noticed in the solid areas of some of the usual ductal hyperplasias.
  • Four of 64 invasive ductal carcinomas (6%) and all metaplastic carcinomas (n = 3, 100%) showed a variable degree of p75(NTR) positivity.
  • No p75NTR expression was found in the malignant cells in all in situ carcinomas, invasive lobular carcinomas (n = 11), tubular carcinomas (n = 10), invasive papillary carcinomas (n = 6), mucinous carcinomas (n = 4), and medullary carcinomas (n = 2).
  • Our study shows that p75NTR is a useful marker for breast myoepithelial cells and can be used to rule out invasive disease as well as to evaluate difficult for diagnosis sclerosing lesions.
  • Our data suggest a role of neurotrophins in the development of fibroepithelial breast tumors and some of the breast carcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Breast / pathology. Breast Neoplasms / pathology. Epithelial Cells / pathology. Muscle, Smooth / pathology. Receptor, Nerve Growth Factor / metabolism
  • [MeSH-minor] Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Humans. Hyperplasia / metabolism. Hyperplasia / pathology. Immunoenzyme Techniques. Myosin Heavy Chains / metabolism. Papilloma, Intraductal / metabolism. Papilloma, Intraductal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258511.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptor, Nerve Growth Factor; EC 3.6.4.1 / Myosin Heavy Chains
  •  go-up   go-down


54. Liu F, Cui L, Zhang Y, Chen L, Wang Y, Fan Y, Lei T, Gu F, Lang R, Pringle GA, Zhang X, Chen Z, Fu L: Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma. Breast Cancer Res Treat; 2010 Dec;124(3):677-88
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
  • HAb18G is a recently identified hepatoma-associated antigen and its association with tumor growth, invasion, and angiogenesis has been studied in a variety of tumors.
  • However, its role in the tumor progression of breast cancer has not been explored.
  • HAb18G expression was examined by immunohistochemistry in pathological sections of 1,637 breast tissue samples and by in situ hybridization in 41 cases of invasive breast carcinomas (BC).
  • While not detected in any cases of tumor-like conditions or benign tumors of breast, and only rarely in normal tissue (4.4%), HAb18G expression was gradually up-regulated from atypical ductal hyperplasia (27.3%), to ductal carcinoma-in situ (59.8%), and to BC (61.4%) (P < 0.01).
  • Significant differences of expression were also identified among the subgroups of BC examined: in decreasing order from invasive micropapillary carcinoma, ductal carcinoma, lobular carcinoma, papillary carcinoma, medullary carcinoma, to mucinous adenocarcinoma (P = 0.001), corresponding to their known clinical aggressiveness.
  • Further evaluation of this new marker in breast cancer is indicated.
  • [MeSH-major] Antigens, CD147 / analysis. Biomarkers, Tumor / analysis. Breast Neoplasms / immunology. Carcinoma / immunology. Carcinoma, Intraductal, Noninfiltrating / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. China. Disease-Free Survival. Female. Humans. Immunohistochemistry. In Situ Hybridization. Kaplan-Meier Estimate. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Retrospective Studies. Time Factors. Treatment Outcome. Up-Regulation. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20213083.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BSG protein, human; 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 136894-56-9 / Antigens, CD147; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


55. Obenauer S, Sohns C, Werner C, Grabbe E: Computer-aided detection in full-field digital mammography: detection in dependence of the BI-RADS categories. Breast J; 2006 Jan-Feb;12(1):16-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The object of this study was to determine the performance of a computer-aided detection system in full-field digital mammography (Senographe 2000D, General Electric, Buc, France) in detecting carcinomas in breasts in dependence of the initial Breast Imaging Reporting and Data System (BI-RADS) categories.
  • A total of 226 mediolateral oblique (MLO) and 186 craniocaudal (CC) view mammograms of histologically proven cancers were retrospectively evaluated with a primary digital computer-aided detection system (Image Checker V2.3; R2 Technology, Los Altos, CA).
  • With increasing BI-RADS category, the computer-aided detection system shows decreasing numbers of overlooked carcinomas.
  • [MeSH-major] Breast Neoplasms / radiography. Mammography / standards. Radiographic Image Interpretation, Computer-Assisted / standards
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radiography. Adult. Aged. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / radiography. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / radiography. Carcinoma, Lobular / pathology. Carcinoma, Lobular / radiography. Carcinoma, Medullary / pathology. Carcinoma, Medullary / radiography. Carcinoma, Papillary / pathology. Carcinoma, Papillary / radiography. False Positive Reactions. Female. Hemangiosarcoma / pathology. Hemangiosarcoma / radiography. Humans. Middle Aged. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16409582.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Fenton H, Carlile B, Montgomery EA, Carraway H, Herman J, Sahin F, Su GH, Argani P: LKB1 protein expression in human breast cancer. Appl Immunohistochem Mol Morphol; 2006 Jun;14(2):146-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LKB1 protein expression in human breast cancer.
  • Peutz-Jeghers syndrome is associated with an increased risk of developing intestinal and extraintestinal cancers, including pancreatic, lung, and breast carcinomas.
  • LKB1 gene inactivation has recently been demonstrated in a subset of sporadic pancreatic and lung carcinomas.
  • The role of the LKB1 gene in sporadic breast carcinomas remains unclear, though recent studies suggest inactivation only within papillary carcinomas.
  • Using a commercially available polyclonal antibody that has been shown to mirror LKB1 genetic status in gastrointestinal and pulmonary carcinomas, the authors performed IHC on a large series of breast cancers using tissue microarrays (TMAs).
  • All abnormal TMA results were confirmed using whole sections; specifically, whole sections from the donor blocks of lesions demonstrating diminished or absent LKB1 protein expression on TMA were evaluated to compare labeling of the lesion with that of the surrounding normal breast.
  • In all cases, normal breast epithelium demonstrated strong cytoplasmic labeling (providing an internal positive control), whereas the stroma was nonreactive.
  • Among 70 invasive ductal carcinomas, 3 (4.3%) showed complete loss of LKB1 labeling, whereas 6 others (8.6%) showed diminished labeling.
  • Of the eight intraductal carcinoma lesions adjacent to these invasive carcinomas, one (12.5%) showed complete loss of LKB1 labeling and one other (12.5%) showed diminished labeling; these results were identical to those of the adjacent invasive carcinomas.
  • One of 10 (10%) hematogenous metastases of mammary carcinoma showed loss of LKB1 labeling.
  • Nine of the 10 invasive carcinomas and both of the ductal carcinoma in situ (DCIS) cases showing loss of or diminished LKB1 expression were of high grade.
  • In contrast, all 13 pure nonpapillary DCIS lesions, all 5 invasive lobular carcinomas and 3 accompanying lobular carcinoma in situ lesions, all 7 papillary DCIS lesions, and all 3 papillomas evaluated showed intact LKB1 labeling.
  • Therefore, although frequent methylation of the LKB1 gene has been reported in papillary carcinomas of the breast, the authors did not find loss of protein expression in these lesions.
  • Instead, it was found that loss of LKB1 protein expression occurs in a subset of high-grade in situ and invasive mammary carcinomas.
  • The authors found LKB1 gene methylation in several of these invasive carcinomas.
  • Given recent Western blot results indicating that diminished LKB1 expression in breast carcinomas correlates with shorter relapse-free survival, LKB1 IHC merits evaluation as a potential prognostic marker for breast carcinoma.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785781.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA88843
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.- / STK11 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


57. Moriya T, Kasajima A, Ishida K, Kariya Y, Akahira J, Endoh M, Watanabe M, Sasano H: New trends of immunohistochemistry for making differential diagnosis of breast lesions. Med Mol Morphol; 2006 Mar;39(1):8-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New trends of immunohistochemistry for making differential diagnosis of breast lesions.
  • Immunohistochemistry is widely used for pathological diagnosis of breast lesions.
  • Other than hormone receptors and HER2/neu analysis for primary breast carcinomas, several markers may be useful for differential diagnoses, although in limited situations.
  • To decide the malignant potential of intraductal proliferative lesions, analysis for the staining pattern of cytokeratins may be a good reference.
  • Most ductal carcinoma in situ cases are diffusely positive for luminal cell markers (CK8, CK18, CK19), but negative for basal cell markers (CK5/6 and CK14).
  • However, usual ductal hyperplasia may show the mosaic staining patterns for any of these markers, which may indicate a heterogeneous cell population in benign lesions.
  • Myoepithelial markers (alpha-SMA, myosin, calponin, p63, CD10) are almost consistently positive for benign papillomas but they do not completely distinguish intraductal papillary carcinomas.
  • Preservation of myoepithelial layer is the diagnostic key when looking at benign sclerosing lesions, including carcinoma with pseudoinvasive structures.
  • E-cadherin is mostly positive for ductal carcinomas but negative for lobular carcinomas.
  • Some of the lobular carcinomas are positive for 34betaE12, but they are consistently negative for CK5/6.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Immunohistochemistry / trends
  • [MeSH-minor] Biomarkers, Tumor. Carcinoma, Lobular / pathology. Diagnosis, Differential. Humans. Papilloma, Intraductal / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575508.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 40
  •  go-up   go-down


58. Böttger T, Terzic A, Müller M: [Laparoscopic pancreatic resection]. Zentralbl Chir; 2006 Aug;131(4):309-14
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologic examination showed a neuroendocrine carcinoma, a serous-microcystic adenoma, a low differentiated ductal adenocarcinoma and an intraductal papillary-mucinous tumor of borderline type.
  • CONCLUSION: Laparoscopic resection of distal pancreas shows the common benefit of minimal invasive surgery for the early postoperative period and is an attractive alternative for treatment of benign and semimalign pancreatic tumors.
  • [MeSH-major] Adenoma / surgery. Carcinoma, Ductal, Breast / surgery. Carcinoma, Neuroendocrine / surgery. Cystadenoma, Mucinous / surgery. Laparoscopy. Pancreas / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Fundoplication. Gastroesophageal Reflux / surgery. Humans. Length of Stay. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Male. Middle Aged. Minimally Invasive Surgical Procedures. Positron-Emission Tomography. Radiography, Abdominal. Spleen / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17004190.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


59. Kamal RM, Abdel Razek NM, Hassan MA, Shaalan MA: Missed breast carcinoma; why and how to avoid? J Egypt Natl Canc Inst; 2007 Sep;19(3):178-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Missed breast carcinoma; why and how to avoid?
  • Causes of missed breast cancer on mammography can be secondary to many factors including those related to the patient (whether inherent or acquired), the nature of the malignant mass itself, poor mammographic techniques, provider factors or interpretive skills of radiologists and oncologists (including perception and interpretation errors).
  • Aim of Work : The aim of this study is to investigate the aforementioned factors hindering early breast cancer detection and in turn lowering mammographic sensitivity and to outline the major guidelines to overcome these factors aiming to an optimum mammographic examination and interpretation by radiologists and oncologists.
  • We included 152 histopathologicaly proven breast carcinomas that were initially missed on mammography.
  • Results : Revision of the pathological specimens of these 152 cases revealed 121 infiltrating ductal carcinomas, 2 lobular, 4 mucinous, 14 inflammatory carcinomas, 6 carcinomas in situ (3 of which were intracystic), 2 intraductal papillary carcinomas and 3 cases with Paget's disease of the nipple.
  • In analyzing the causes responsible for misdiagnosis of these carcinomas we classified them into 4 causative factors; patient, tumor, technical or provider factors.
  • Carcinomas were detected using several individual or combined complementary techniques.
  • Forty four carcinomas were detected on double and re-reading by more experienced radiologists.
  • Complementary ultrasound examination was performed for all 152 cases (100%) and showed a higher sensitivity than mammography in carcinoma detection.
  • Conclusion : Why can breast carcinoma be missed?
  • Four main factors are responsible for missing a carcinoma:.
  • (1) Patient factors (Inherently dense breasts or acquired dense breasts). (2) Tumor factors (subtle carcinoma, masked carcinoma, multifocal carcinoma and multicentric carcinoma). (3) Technical factors (bad exposure factors, malpositioned breasts and bad processing quality). (4) Provider factors (bad perception and misinterpretation).
  • How to avoid missing a breast carcinoma?
  • Be alert to subtle features of breast cancers.
  • Always consider the well defined carcinoma.
  • Look for other lesions when one abnormality is seen.
  • Close cooperation between the oncologist, radiologist and pathologist is essential to avoid missing any case of breast carcinoma.
  • Key Words : Missed breast carcinoma -Mammography - Ultrasonography -MRI.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190691.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


60. Zhong L: Magnetic resonance imaging in the detection of pancreatic neoplasms. J Dig Dis; 2007 Aug;8(3):128-32
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The non-invasive all-in-one MR multi-imaging techniques may provide the comprehensive information needed for the preoperative diagnosis and evaluation of pancreatic neoplasms.
  • Primary tumors of the pancreas may be mainly classified as ductal adenocarcinomas, cystic tumors and islet cell tumors (ICT).
  • Pancreatic adenocarcinomas can be diagnosed in a MRI study depending on direct evidence or both direct and indirect evidence.
  • The combined MRI features of a focal pancreatic mass, pancreatic duct dilatation and parenchymal atrophy are highly suggestive of a ductal adenocarcinoma.
  • Intraductal papillary mucinous tumors are the uncommon low-grade malignancy of the pancreatic duct.
  • ICT are classified as functioning and non-functioning.
  • The most frequent tumors to metastasize to the pancreas are cancers of the breast, lung, kidney and melanoma.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / pathology. Humans. Neoplasms, Cystic, Mucinous, and Serous / diagnosis. Neoplasms, Cystic, Mucinous, and Serous / pathology. Pancreas / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17650223.001).
  • [ISSN] 1751-2972
  • [Journal-full-title] Journal of digestive diseases
  • [ISO-abbreviation] J Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 10
  •  go-up   go-down


61. Partelli S, Fernandez-Del Castillo C, Bassi C, Mantovani W, Thayer SP, Crippa S, Ferrone CR, Falconi M, Pederzoli P, Warshaw AL, Salvia R: Invasive intraductal papillary mucinous carcinomas of the pancreas: predictors of survival and the role of lymph node ratio. Ann Surg; 2010 Mar;251(3):477-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive intraductal papillary mucinous carcinomas of the pancreas: predictors of survival and the role of lymph node ratio.
  • INTRODUCTION: Intraductal papillary mucinous neoplasms (IPMNs) are being increasingly recognized, and often harbor cancer.
  • Lymph node metastases are an important prognostic factor for patients with invasive intraductal papillary carcinoma (I-IPMC), but the role of lymph node ratio (LNR) in predicting survival after surgery for I-IPMC is unknown.
  • On multivariate analysis, LNR, the presence of a family history of pancreatic cancer and a preoperative value of Ca 19.9 > 37 U/L were significant predictors of survival (P < 0.05).
  • CONCLUSIONS: Lymph node ratio is a strong predictor of survival after resection for invasive intraductal papillary mucinous carcinoma.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1077-85 [14597447.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):168-78 [15185076.001]
  • [Cites] Am J Surg. 2005 May;189(5):632-6; discussion 637 [15862510.001]
  • [Cites] Surgery. 2005 Jul;138(1):8-13 [16003309.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Ann Surg Oncol. 2006 Jul;13(7):955-60 [16788757.001]
  • [Cites] Ann Surg. 2007 Apr;245(4):543-52 [17414602.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):338-44 [17458608.001]
  • [Cites] Surgery. 2007 May;141(5):610-8 [17462460.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):72-9; quiz 309-10 [17631133.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):165-74 [17896141.001]
  • [Cites] Pancreas. 2008 Jan;36(1):50-5 [18192881.001]
  • [Cites] World J Surg. 2008 Feb;32(2):271-8; discussion 279-80 [18027021.001]
  • [Cites] Ann Surg. 2008 Feb;247(2):365-71 [18216546.001]
  • [Cites] J Gastrointest Surg. 2008 Apr;12(4):645-50 [18097728.001]
  • [Cites] Arch Surg. 2008 Jul;143(7):639-46; discussion 646 [18645105.001]
  • [Cites] Ann Surg Oncol. 2008 Nov;15(11):3178-86 [18712568.001]
  • [Cites] Am J Surg. 1999 Oct;178(4):344-7 [10587197.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):157-63 [11134208.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):376-81 [11260102.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Verh Dtsch Ges Pathol. 2001;85:219-28 [11894402.001]
  • [Cites] Gastrointest Endosc. 2002 May;55(6):701-14 [11979253.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] World J Surg. 2003 Mar;27(3):330-3 [12607061.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • (PMID = 20142730.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK071329-04; United States / NCI NIH HHS / CA / P01 CA117969-04; United States / NCI NIH HHS / CA / P01 CA117969; United States / NIDDK NIH HHS / DK / K08 DK071329; United States / NIDDK NIH HHS / DK / K08 DK071329-05; United States / NCI NIH HHS / CA / P50 CA127003-04; United States / NCI NIH HHS / CA / P50 CA127003-03; United States / NIDDK NIH HHS / DK / K08 DK071329-04; None / None / / P50 CA127003-03; United States / NCI NIH HHS / CA / P50 CA127003; United States / NCI NIH HHS / CA / P01 CA117969-05; United States / NCI NIH HHS / CA / P01 CA117969-04S1
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS288058; NLM/ PMC3135381
  •  go-up   go-down


62. Fadare O, Rose TA, Tavassoli FA: Papillary intraductal carcinoma with extensive secretory endometrium-like subnuclear vacuolization. Breast J; 2005 Nov-Dec;11(6):470-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary intraductal carcinoma with extensive secretory endometrium-like subnuclear vacuolization.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Papillary / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16297096.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Pelosi G, Sonzogni A, Rosai J: Thyroid-type papillary microcarcinoma in ovarian strumal carcinoid. Int J Surg Pathol; 2008 Oct;16(4):435-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid-type papillary microcarcinoma in ovarian strumal carcinoid.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Carcinoid Tumor / pathology. Ovarian Neoplasms / pathology. Struma Ovarii / pathology
  • [MeSH-minor] Aged. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Female. Humans. Immunohistochemistry. Neoplasms, Multiple Primary / metabolism. Neoplasms, Multiple Primary / pathology

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18480390.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


64. Sakamoto G: [Breast neoplasms: histological classification]. Nihon Rinsho; 2007 Jun 28;65 Suppl 6:54-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast neoplasms: histological classification].
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Scirrhous / pathology. Breast Neoplasms / classification. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17682139.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 9
  •  go-up   go-down


65. MacGrogan G: [Diagnostic pitfalls in mammary pathology. Case 1. In situ ductal carcinoma of low nuclear grade, with papillary, micropapillary and cribriform architecture]. Ann Pathol; 2009 Jun;29(3):188-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic pitfalls in mammary pathology. Case 1. In situ ductal carcinoma of low nuclear grade, with papillary, micropapillary and cribriform architecture].
  • [Transliterated title] Pièges diagnostiques en pathologie mammaire. Cas no 1. Carcinome canalaire in situ (CCIS) de bas grade nucléaire, d'architecture papillaire, micropapillaire et cribriforme.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Neoplasms, Multiple Primary / diagnosis. Papilloma / diagnosis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Biomarkers, Tumor / analysis. Carcinoma, Papillary / chemistry. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Cell Nucleus / ultrastructure. Diagnosis, Differential. Female. Humans. Hyperplasia. Keratins / analysis. Membrane Proteins / analysis. Neoplasm Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19619824.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


66. Muradali D, Kulkarni S: Sonography of the breast: to core or not to core? Can Assoc Radiol J; 2005 Dec;56(5):276-88
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonography of the breast: to core or not to core?
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Ultrasonography, Mammary
  • [MeSH-minor] Adenocarcinoma, Mucinous / ultrasonography. Algorithms. Artifacts. Biopsy. Breast Diseases / ultrasonography. Carcinoma, Ductal, Breast / ultrasonography. Carcinoma, Papillary / ultrasonography. Diagnosis, Differential. Fibroadenoma / ultrasonography. Hamartoma / ultrasonography. Humans. Lipoma / ultrasonography. Lymphatic Metastasis / ultrasonography. Lymphoma / ultrasonography. Magnetic Resonance Imaging. Neoplasm Metastasis / ultrasonography. Papilloma, Intraductal / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16579021.001).
  • [ISSN] 0846-5371
  • [Journal-full-title] Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes
  • [ISO-abbreviation] Can Assoc Radiol J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


67. Yamaguchi Y, Abe N, Imase K, Mizuno H, Chinen K, Mori H, Sugiyama M, Atomi Y, Ishida H, Takahashi S: A case of mucin hypersecreting intraductal papillary carcinomas occurring simultaneously in liver and pancreas. Gastrointest Endosc; 2005 Feb;61(2):330-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of mucin hypersecreting intraductal papillary carcinomas occurring simultaneously in liver and pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / secretion. Carcinoma, Papillary / secretion. Liver Neoplasms / secretion. Mucins / secretion. Neoplasms, Multiple Primary / secretion. Pancreatic Neoplasms / secretion

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15729259.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


68. Soesan M, de Snoo F, Westerga J, Floore A, Bender R: Microarray analysis as a helpful tool in identifying the primary tumour in cancer with an unknown primary site. Neth J Med; 2010 Jan;68(1):50-1
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / diagnosis. Gene Expression Profiling. Neoplasms, Unknown Primary / diagnosis. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenocarcinoma / secondary. Aged. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Intraductal, Noninfiltrating / surgery. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / genetics. Carcinoma, Papillary / secondary. Female. Humans. Lung Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20103826.001).
  • [ISSN] 1872-9061
  • [Journal-full-title] The Netherlands journal of medicine
  • [ISO-abbreviation] Neth J Med
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down






Advertisement